Karen J Wilson bought stock once, on May 22, 2026

Karen J. Wilson is an individual corporate insider and Director at Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ drug-delivery platform.( She was appointed to Serina’s Board of Directors in January 2025, bringing more than 30 years of finance and leadership experience in the life sciences industry.( In addition to her role at Serina, Wilson currently serves on the boards of Connect Biopharma Holdings Limited, Elicio Therapeutics, Inc., and LAVA Therapeutics N.V.(

Earlier in her career, Wilson served as Senior Vice President of Finance, Principal Accounting Officer, and Vice President of Finance at Jazz Pharmaceuticals plc, following senior finance positions at PDL BioPharma, ViroLogic, and Novare Surgical Systems.( She began her professional career as a consultant and auditor with Deloitte & Touche LLP and is a Certified Public Accountant.( Wilson holds a B.S. in Business from the University of California, Berkeley, providing the foundation for her longstanding focus on strategic finance and corporate governance in the biotechnology sector.(

Written by Perplexity from public sources.